Abstract
The field of cancer therapy is rapidly moving forward with the development of numerous prospective new agents designed to inhibit cellular factors involved in signal transduction, cell proliferation, and the onset of apoptosis. At the core of these biological processes are transcription factors that are the functional mediators of these effects. Transcription factors are the downstream targets of numerous signal transduction pathways that are central to the process of carcinogenesis. The Activator Protein-1 (AP-1) complex is one such factor that has a central role in multiple processes involved in tumorigenesis including proliferation, migration, invasion and metastasis. The focus of this review is, using AP- 1 as a model, to discuss transcription factors as targets for cancer therapy. The feasibility of targeted disruption of AP-1 by various agents such as dominant-negative mutants, small molecule inhibitors, transcription factor decoys (TFD), chemotherapeutic drugs, chemoprevention agents, siRNA and natural products will be explored.
Keywords: Cancer therapy, transcription factors, AP-1, dominant-negative mutants, TF-decoys, RNAi, small molecule inhibitors
Current Cancer Therapy Reviews
Title: Transcription Factors as Targets for Cancer Therapy: AP-1 a Potential Therapeutic Target
Volume: 3 Issue: 1
Author(s): Virna D. Leaner, Howard Donninger and Michael J. Birrer
Affiliation:
Keywords: Cancer therapy, transcription factors, AP-1, dominant-negative mutants, TF-decoys, RNAi, small molecule inhibitors
Abstract: The field of cancer therapy is rapidly moving forward with the development of numerous prospective new agents designed to inhibit cellular factors involved in signal transduction, cell proliferation, and the onset of apoptosis. At the core of these biological processes are transcription factors that are the functional mediators of these effects. Transcription factors are the downstream targets of numerous signal transduction pathways that are central to the process of carcinogenesis. The Activator Protein-1 (AP-1) complex is one such factor that has a central role in multiple processes involved in tumorigenesis including proliferation, migration, invasion and metastasis. The focus of this review is, using AP- 1 as a model, to discuss transcription factors as targets for cancer therapy. The feasibility of targeted disruption of AP-1 by various agents such as dominant-negative mutants, small molecule inhibitors, transcription factor decoys (TFD), chemotherapeutic drugs, chemoprevention agents, siRNA and natural products will be explored.
Export Options
About this article
Cite this article as:
Leaner D. Virna, Donninger Howard and Birrer J. Michael, Transcription Factors as Targets for Cancer Therapy: AP-1 a Potential Therapeutic Target, Current Cancer Therapy Reviews 2007; 3 (1) . https://dx.doi.org/10.2174/157339407780126665
DOI https://dx.doi.org/10.2174/157339407780126665 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Role of Adiponectin in Cervical Cancer
Current Drug Metabolism Evaluation of High Risk HPV (HPV-16 and -18) RNA and Integration in Cervical Neoplasms in Systemic Lupus Erythematosus
Current Women`s Health Reviews Histone Deacetylase Inhibitors in Cancer Therapy: New Compounds and Clinical Update of Benzamide-Type Agents
Current Topics in Medicinal Chemistry Emerging Role of Circular RNAs in Kidney Diseases in Nephrology
Current Drug Targets Molecular and Cellular Activities of Vitamin E Analogues
Mini-Reviews in Medicinal Chemistry The Role of NF-κB Inhibitors in Cell Response to Radiation
Current Medicinal Chemistry The Type II Transmembrane Serine Protease, Matriptase-2: Possible Links to Cancer?
Anti-Cancer Agents in Medicinal Chemistry Contribution of Catecholamine Reactive Intermediates and Oxidative Stress to the Pathologic Features of Heart Diseases
Current Medicinal Chemistry Melatonin Therapy of Pediatric Sleep Disorders: Recent Advances, Why it Works, Who are the Candidates and How to Treat
Current Pediatric Reviews Anti-Cancer Drug Discovery: Structure, Function and Novel Strategy – Part-3
Current Topics in Medicinal Chemistry Predictive Efficacy Biomarkers of Programmed Cell Death 1/Programmed Cell Death 1 Ligand Blockade Therapy
Recent Patents on Anti-Cancer Drug Discovery Melatonin in the Biliary Tract and Liver: Health Implications
Current Pharmaceutical Design Structure-activity Relationship Studies of New Marine Anticancer Agents and their Synthetic Analogues
Current Medicinal Chemistry The Application of Proteomics in Neurology
Current Proteomics Advances in Hydrogels Applied to Degenerative Diseases
Current Pharmaceutical Design Perinatal Management of Fetal Tumors
Current Pediatric Reviews Potential Pathways for CNS Drug Delivery Across the Blood-Cerebrospinal Fluid Barrier
Current Pharmaceutical Design Synthesis of Medicinally Privileged Heterocycles through Dielectric Heating
Current Medicinal Chemistry Drug Metabolism and Transport Under Hypoxia
Current Drug Metabolism Recent Approaches for Studying the Role of Glia
CNS & Neurological Disorders - Drug Targets